Casgevy opens to children as the first commercial CRISPR therapy finds its steady state

The headline claim is narrow: one hundred percent of 45 evaluable sickle cell patients in the CLIMB-121 and CLIMB-131 studies have now gone vaso-occlusive-crisis-free, with mean duration on the order of thirty-five months and a maximum north of five and a half years. What the number signals is broader. Casgevy is no longer a proof point. It is a programme, with an age-expansion filing, a pediatric infusion cadence, and the first signs of what a durable CRISPR market actually looks like.

Vertex presented the first-ever pivotal data in children aged five to eleven at the American Society of Hematology annual meeting in December 2025, and has signalled global regulatory submissions for the pediatric indication over the course of 2026. The US authorised treatment centre network has also quietly thickened: Northwell's Cohen Children's Medical Center administered New York State's first commercial Casgevy infusion in December 2025, and Nationwide Children's in Columbus completed its first pediatric commercial case the same year. The NHS pathway in England opened in January 2025 for a subset of eligible severe sickle cell patients.

The clinical bar was always the easy part. The operational bar — conditioning regimens, apheresis capacity, bone-marrow transplant beds, insurance prior-authorisation rules tuned for a one-time $2.2 million intervention — is where programmes like this usually stall. That bar, according to treating centres, is being slowly overbuilt. Vertex has expanded the authorised treatment centre count through 2025, and is walking payers through the actuarial case that a durable one-time cure is cheaper than a lifetime of crisis admissions. The argument is not subtle, and the payers appear, slowly, to be accepting it.

The winners are the patients, who are no longer debating whether the therapy exists, only whether they qualify. The secondary winners are the CROs and apheresis providers who run the peri-infusion workflow for Vertex and for the next wave of ex vivo programmes. The losers, in a narrow sense, are the chronic transfusion and hydroxyurea supply chains — though the loss is at the edges, because eligibility remains tight.

What the expansion forecloses is the argument that CRISPR medicines cannot scale beyond a handful of heroic cases. What it opens is the harder debate about who, globally, will actually get treated. Sickle cell disease is concentrated in populations and geographies that are not the ones in which Casgevy currently ships. The next five years will be about closing that gap, or failing to.